Status:
ACTIVE_NOT_RECRUITING
Easy Access to Smoking Cessation for People Receiving Opioid Agonist Therapy Who Are Smoking Tobacco
Lead Sponsor:
Haukeland University Hospital
Collaborating Sponsors:
Helse Stavanger HF
Helse Vest
Conditions:
Smoking Cessation
Substance-Related Disorders
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Background: About 85% of those receiving opioid agonist therapy (OAT) for opioid dependence are smoking tobacco. Cigarette smoke lead to lunge diseases and cause illness and death within this group. B...
Detailed Description
Background: About 85% of those receiving opioid agonist therapy (OAT) for opioid dependence are smoking tobacco. Smoke-related pulmonary diseases are significant contributors to morbidity and mortalit...
Eligibility Criteria
Inclusion
- Receiving OAT from an included outpatient clinic with weekly follow-up
- Smoking at least one cigarette per day or seven cigarettes per week
- Obtaining informed consent
Exclusion
- Allergies or prior anaphylactic reactions to medication used
- Smoking less than three times a week
Key Trial Info
Start Date :
April 7 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2026
Estimated Enrollment :
266 Patients enrolled
Trial Details
Trial ID
NCT05290025
Start Date
April 7 2022
End Date
December 1 2026
Last Update
June 28 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Addiction Medicine, Haukeland University Hospital
Bergen, Norway, 5021
2
LAR Helse Stavanger HF
Stavanger, Norway, 4010